Whether V227A-mediated plasma triglyceride reduction imparts any long-term cardiometabolic protection is not yet known, but there is clinical interest in promoting LPL activity for the prevention of cardiovascular disease (56, 57). Here, LPL is linked to cardiovascular disorder.